Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 6 Nov 2019 |
| Genmab Announces Financial Results for the First Nine Months of 2019 | 6 Nov 2019 |
| Genmab’s Financial Calendar for 2020 | 30 Oct 2019 |
| David Eatwell to Retire as Chief Financial Officer of Genmab | 30 Oct 2019 |
| Genmab A/S has published its Articles of Association | 22 Oct 2019 |
| CHMP Issues Positive Opinion Recommending DARZALEX® (Daratumumab) in Combination with Lenalidomide and Dexamethasone in Frontline Multiple Myeloma | 18 Oct 2019 |